Please assess the completion status of the following clinical trial:

Trial Title: Escitalopram for Premenstrual Syndrome (PMS) in Teens: A Pilot Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Females 15-19 years of age~* Regular menstrual cycles of 22-35 days~* In general good health~* Medically approved birth control method if sexually active~* Evidence of ovulation~* Meeting all symptom criteria for PMS~* Signed informed consent~* Subjects under age 18 must also have signed parental consent~Exclusion Criteria:~* Current use of any treatment for PMS.~* Psychotropic or other medications that may compromise the study drug.~* Pregnancy, intending pregnancy or breast feeding.~* Not using a medically approved birth control method if sexually active.~* Significant medical or gynecological abnormalities.~* Irregular menses, any gynecologic disorder.~* Any severe or unstable medical illness.~* Any current major psychiatric diagnosis or any history of a major psychiatric diagnosis.~* Any current or history of alcohol abuse, drug abuse, suicide attempt, bi-polar disorder, psychosis or severe personality disorder.~* Use of triptans (Imitrex, Zomig, Frova, Maxalt, Axert, Amerge, Relpax).~* Use of medicines that include dextromethorphan such as Tylenol or Vicks cough medicines.~* Use of the pain medication meperidine.~* Use of any herbal product such as St John's Wort that may increase serotonin.~* Use of monoamine oxidase inhibitors (MAOIs), pimozide or citalopram hydrobromide.~* Drugs metabolized by CYP2D6 or a combination of CYP3A4 and CYP2D6 inhibitors.~* Hypersensitivity to escitalopram or citalopram.

- Gender: FEMALE
- Minimum Age: 15 Years
- Maximum Age: 19 Years
- Healthy Volunteers: f

Study Arms:
- escitalopram (Type: EXPERIMENTAL): Escitalopram 10 mg tablets taken once daily. Dosing in the luteal phase of the menstrual cycle (estimated day 14 to day 2). Start at 10 mg/day (1 tablet) in the first treatment cycle. If unimproved, increase to 20 mg/day (2 tablets) in cycle 2 if not precluded by side effects.
- placebo (Type: PLACEBO_COMPARATOR): Placebo tablets matched to drug.

Based on this trial design, predict the completion outcome and termination type (if applicable).